ImClone Finds Itself Facing Another Erbitux Patent Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott alleges cell line used to manufacture cetuximab violates one of its patents.
You may also be interested in...
Repligen Settles With ImClone On Erbitux Suit
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.
Repligen Settles With ImClone On Erbitux Suit
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.
Erbitux Patent Holder Yeda Responds to ImClone Suit
Company demands treble damages and non-exclusive licensing deal.